Back to discover
Drug

Paricalcitol

Approved · FDA
ClassVitamin D receptor agonistEmerging researchLate-stage developmentSteady momentum

Also known as 19-Nor-1alpha,25-dihydroxyvitamin D2, Zemplar.

RxNorm73710ChEMBLCHEMBL1200622ATCH05BX02UNII6702D36OG5
4
Research papers
2
Active clinical trials
Vitamin D3 receptor
Primary target
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Label change: PARICALCITOL (NDA205917)

Regulatory2026-06-17FDA

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)

Clinical trial2026-05-12Results posted · ClinicalTrials.gov

Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer

Clinical trial2026-01-23Results posted · ClinicalTrials.gov

The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients -a Randomised Placebo Controlled Trial

Clinical trial2025-10-01Primary completion · ClinicalTrials.gov

A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Clinical trial2025-08-27Results posted · ClinicalTrials.gov

A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

Clinical trial2025-06-09Terminated · ClinicalTrials.gov

Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.

Research2025-01-01The oncologist

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.

Research2017-03-22Pediatric nephrology (Berlin, Germany)

Approval: PARICALCITOL (NDA205917)

Regulatory2014-11-18FDA

Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.

Research2012-08-22Kidney international

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.

Research2008-07-07Hypertension (Dallas, Tex. : 1979)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Paricalcitol
Aliases & brands
19-Nor-1alpha,25-dihydroxyvitamin D2Zemplar
RxNorm CUI
73710
ChEMBL ID
CHEMBL1200622
ATC codes
H05BX02
UNII
6702D36OG5
Primary mechanism
Vitamin D receptor agonist
Regulatory jurisdictions
fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vitamin D3 receptor
VDR · P11473
AGONISTVitamin D receptor agonist

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2014-11-18
Latest approval
2014-11-18
Authorities
FDA
Total events
2
fdaU.S. Food and Drug Administration· 2 events
2026-06-17Label change
Label change: PARICALCITOL (NDA205917)
Evidence ↗
2014-11-18Approval
Approval: PARICALCITOL (NDA205917)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

89 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
89
registered trials across all phases
LATEST COMPLETION 2025
2
Active studies
2
Recruiting
57
Late-stage (III+)
67
Completed
20
Discontinued
PHASE DISTRIBUTIONn = 89
Early Phase 12Phase 110Phase 220Phase 2 / 31Phase 320Phase 426Phase N / A10

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Benefits of the Paricalcitol (Selective Vitamin D Receptor Activator) on Anemia of Inflammation in Dialysis Patients Under Erythropoiesis-stimulating Agents Treatment.

TerminatedPH IVHospital Son Espasesn=192024

An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency

CompletedPH IVOPKO Health, Inc.n=692020

Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs

Unknown statusPH IVThe University of Hong Kongn=302018

A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients

CompletedPH IVAbbVie (prior sponsor, Abbott)n=652016

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.

CompletedPH IVFundación Senefron=1482015

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

CompletedPH IIBarts & The London NHS Trustn=272025

A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

CompletedPH IIHonorHealth Research Instituten=352024

A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)

CompletedPH IIHonorHealth Research Instituten=342023

Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer

CompletedPH IIEmory Universityn=102023

A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer

CompletedPH IM.D. Anderson Cancer Centern=92023

Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

CompletedPH IICancer Trials Irelandn=152022

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20082025
Major research themes7
Antibodies, Monoclonal, Humanized1Antineoplastic Combined Chemotherapy Protocols1Carcinoma, Pancreatic Ductal1Cytoreduction Surgical Procedures1Ergocalciferols1Pancreatic Neoplasms1Renal Dialysis1
Journals, researchers & institutions
Top journals
  • Hypertension (Dallas, Tex. : 1979)1
  • Kidney international1
  • Pediatric nephrology (Berlin, Germany)1
  • The oncologist1
Leading researchers
  • Agarwal R1
  • Alborzi P1
  • Alistar A1
  • Ariceta G1
  • Barrett MT1
  • Becerra C1
  • Bekele DM1
  • Bills JE1
Leading institutions
free-text, unnormalised
  • Atlantic Medical Group-Oncology Morristown Medical Center1
  • Center for Pediatric Nephrology1
  • Children's Mercy Hospital1
  • City of Hope National Medical Center1
  • Department of Paediatric Nephrology and NIHR/Wellcome Trust Clinical Research Facility1
  • Division of Nephrology and Kidney Research Institute1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Pembrolizumab

Studied across 3 of the same disease areas as Paricalcitol in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.